CapsoVision, Inc

CapsoVision, IncCVEarnings & Financial Report

Nasdaq · Health Care · Electromedical & Electrotherapeutic Apparatus

CapsoVision, Inc. is a medical technology firm specializing in the development and manufacturing of advanced capsule endoscopy systems and supporting diagnostic solutions. Its non-invasive gastrointestinal imaging products are supplied to hospitals, gastroenterology clinics and medical specialists across global markets, supporting more accurate detection of digestive diseases and improved patient care experiences.

CV Q3 FY2025 Key Financial Metrics

Revenue

$3.5M

Gross Profit

$1.9M

Operating Profit

$-8.0M

Net Profit

$-7.9M

Gross Margin

54.1%

Operating Margin

-226.7%

Net Margin

-223.9%

YoY Growth

N/A

EPS

$-0.17

CapsoVision, Inc Q3 FY2025 Financial Summary

CapsoVision, Inc reported revenue of $3.5M for Q3 FY2025, with a net profit of $-7.9M (-223.9% margin). Cost of goods sold was $1.6M, operating expenses totaled $9.9M.

Key Financial Metrics

Total Revenue$3.5M
Net Profit$-7.9M
Gross Margin54.1%
Operating Margin-226.7%
Report PeriodQ3 FY2025

Revenue Breakdown

CapsoVision, Inc Q3 FY2025 revenue of $3.5M breaks down across 2 segments, led by Products at $2.5M (71.1% of total).

SegmentRevenue% of Total
Products$2.5M71.1%
Other$1.0M28.9%

CapsoVision, Inc Revenue by Segment — Quarterly Trend

CapsoVision, Inc revenue by segment across the last 2 reported quarters, showing how each business line (such as Products and Other) has evolved quarter over quarter.

SegmentQ3 FY2025Q2 FY2025
Products$2.5M$2.4M
Other$1.0M$962.0K

CapsoVision, Inc Quarterly Revenue & Net Profit History

CapsoVision, Inc results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$3.5M$-7.9M-223.9%
Q2 FY2025$3.3M$-4.6M-139.5%

Income Statement

Q2 2025Q3 2025
Revenue$3.3M$3.5M
YoY GrowthN/AN/A

Balance Sheet

Q2 2025Q3 2025
Assets$9.5M$25.7M
Liabilities$4.9M$5.2M
Equity$-139.0M$20.4M

Cash Flow

Q2 2025Q3 2025
Operating CF$-9.5M$-5.7M